AbCellera

AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Translation, Bispecific monoclonal antibody, Orange County Convention Center, AACR, Senior, ABCL, TCE, Antibody, Patient, Translational research, Trichloroethylene, Poster, Society, Vaccine, Dry cleaning, Partnering, AbCellera, PMHC cellular microarray

AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.

Key Points: 
  • AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.
  • AbCellera debuted its TCE platform at AACR 2022 with data describing the diversity of its CD3-binding antibodies.
  • Presentations at AACR 2023 illustrated how AbCellera streamlines the development of TCEs with optimal functional properties for diverse tumor targets.
  • The presentation included:
    A comprehensive data package on a panel of CD3-binding antibodies, including binding and functional comparisons to molecules commonly used for TCE development.

AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023

Retrieved on: 
Tuesday, April 11, 2023
Biotechnology, Health Technology, Pharmaceutical, Health, Conference, ABCL, Cryptocurrency, Broadcasting, AbCellera

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).
  • A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website .
  • A replay will be available through the same link following the presentation.

AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

Retrieved on: 
Thursday, April 6, 2023
Biotechnology, Health Technology, Pharmaceutical, Health, ABCL, Communications satellite, Video game, Cryptocurrency, AbCellera

AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Key Points: 
  • AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
  • A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website .
  • A replay will be available through the same link following the conference call.

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

Retrieved on: 
Wednesday, March 22, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Partnership, Cytomegalovirus, ABCL, Infection, RQ, Record, Multimedia, Antibody, Patient, Risk, CMV, Death, Vaccine, Pharmaceutical industry, AbCellera

AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).

Key Points: 
  • AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).
  • The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly potent antibodies.
  • “AbCellera’s discovery engine complements RQ Bio’s capabilities and provides a technology advantage that we believe will help bring new medicines for infectious disease to patients faster.”
    “Both RQ Bio and AbCellera have proven track records in developing infectious disease medicines that have a rapid impact on vulnerable patients,” said Hugo Fry, CEO of RQ Bio.
  • AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.

AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, American Association for Cancer Research, PMHC cellular microarray, AACR, Orange County Convention Center, Antibody, ABCL, Vaccine, AbCellera

AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets.

Key Points: 
  • AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets.
  • Additionally, AbCellera will present data on the discovery and characterization of antibodies against MAGE-A4, a validated peptide-MHC (pMHC) target for cancer treatment.
  • Together, these two presentations illustrate how AbCellera’s CD3 panel integrates with its antibody discovery and development engine to streamline T-cell engager development.
  • Details on AbCellera’s poster presentations at AACR are as follows:
    Date and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m.

Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Research and development, Geographic atrophy, Retirement, Corporation, DSM-IV codes, G&A, Therapy, Administration, Acquisition, AbCellera, Research, General Administration of Sport of China, HPP, Woman, ENPP1, Paratriathlon, Rare, Patient, Risk, Pharmacokinetics, Hypophosphatasia, Disease, Hematology, Male, Quarter, Pregnancy, R, CFO, Female, CPA, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency, IND

In the fourth quarter of 2022, we initiated a multiple ascending dose Phase 1 study of RLYB116, our inhibitor of complement component 5 (C5), and we look forward to sharing initial data from this study in the fourth quarter of 2023.

Key Points: 
  • In the fourth quarter of 2022, we initiated a multiple ascending dose Phase 1 study of RLYB116, our inhibitor of complement component 5 (C5), and we look forward to sharing initial data from this study in the fourth quarter of 2023.
  • The Company expects results from this cohort of subjects in the fourth quarter of 2023.
  • Rallybio initiated dosing in the first multiple ascending dose cohort of a Phase 1 study of RLYB116 in the fourth quarter of 2022.
  • Fourth Quarter and Full Year 2021 Financial Results:
    Research & Development (R&D) Expenses: R&D expenses were $10.8 million for the fourth quarter of 2022, compared to $6.1 million for the same period in 2021.

Creating good jobs in health research and innovation

Retrieved on: 
Monday, February 27, 2023
Local government in Canada, Infection, National Research Council Canada, Safety, Government, Cancer, Rare, Metabolism, Pandemic, AbCellera, Strategic Innovation Fund, Mental, Research, Investment, Growth, Environment, Therapy, AstraZeneca, Federation, Messenger, Sanofi, Vaccine, Health, Pharmaceutical industry

MISSISSAUGA, ON, Feb. 27, 2023 /CNW/ - When innovation and investments in health research come together to create good middle-class jobs, everyone benefits.

Key Points: 
  • MISSISSAUGA, ON, Feb. 27, 2023 /CNW/ - When innovation and investments in health research come together to create good middle-class jobs, everyone benefits.
  • We will continue to grow the economy, create good jobs, and improve the health of Canadians now and into the future.
  • That's exactly why we're here today: We're positioning Canada as a world leader in the sector, delivering better health outcomes for Canadians, and creating good jobs now and into the future."
  • We're proud to see the results of our Biomanufacturing and Life Sciences Strategy, whilst creating hundreds of well-paying jobs in Mississauga."

Carterra Expands Best-in-Class Franchise With the Launch of the LSAXT High-Throughput SPR Biosensor at SLAS 2023

Retrieved on: 
Monday, February 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, DEL, Society, Therapy, Atomic mass, CDC, Bamlanivimab, AbCellera, Exhibition, Cell, Software, Risk, Drug discovery, Kinetics, Marketing, Eli Lilly, SPR, COVID-19, ChromeOS, FC, ADCP, Inc., Science, Laboratory automation, Conference, SLAS, Antibody, Membrane, Cytokine, ADCC, LSA, Fine chemical, Pharmaceutical industry, Nature

Carterra will be showcasing the new LSAXT platform for high-throughput SPR at the SLAS event (booth 2127) with a launch program that includes a user presentation by Dragonfly Therapeutics on February 27 at 2:00 pm.

Key Points: 
  • Carterra will be showcasing the new LSAXT platform for high-throughput SPR at the SLAS event (booth 2127) with a launch program that includes a user presentation by Dragonfly Therapeutics on February 27 at 2:00 pm.
  • Speaking about the launch of the LSAXT at SLAS 2023, Christopher Silva, Vice President of Marketing and Product at Carterra added, “This is a great day for biologics discovery scientists and for Carterra.
  • You always run the risk of missed expectations when you launch a follow-on product after a game changer like the LSA.
  • But we’ve proved that with the LSAXT the story only gets better for us and our customers.”

AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

Retrieved on: 
Thursday, February 23, 2023
Biotechnology, Pharmaceutical, Health, ABCL, Conference, Cryptocurrency, Broadcasting, AbCellera

AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
  • A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website .
  • A replay will be available through the same link following the presentation.

AbCellera Reports Full Year 2022 Business Results

Retrieved on: 
Tuesday, February 21, 2023
Biotechnology, Pharmaceutical, Health, General Administration of Sport of China, Bamlanivimab, AbCellera, Partnership, Research, Webcast, S&M, Research and development, Investment, Bebtelovimab, R, Growth, Sales & Marketing Executives International, EUA, Administration, COVID-19, G&A, Video game, Reinsurance, Pharmaceutical industry

AbCellera started discovery on 23 partnered programs in 2022 to reach a cumulative total of 101 partnered program starts (up 29% from 78 on December 31, 2021).

Key Points: 
  • AbCellera started discovery on 23 partnered programs in 2022 to reach a cumulative total of 101 partnered program starts (up 29% from 78 on December 31, 2021).
  • AbCellera’s partners advanced an additional three molecules into the clinic in 2022, bringing the cumulative total to eight molecules in the clinic.
  • Revenue for the fourth quarter of 2022 was $21.5 million, representing 4% of the total for 2022.
  • AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).